Hengrui Medicine Says HRS-2189 Tablet Received Clinical Trial Approval
Hengrui Medicine said it received a clinical trial approval notice for HRS-2189 tablets.
Related stories
A. O. Smith Reports Q3 Adjusted Earnings, Revises 2026 EPS Guidance
A. O. Smith reported Q3 adjusted earnings and revised full-year 2026 adjusted EPS guidance to exclude its China business. The headline also reports a drop in net sales but gives no
M impact | EQUITY | Oct 29, 2026, 01:28 PM UTC
IndiGo Reports Rs 1,879 Crore Q2 Loss as Fuel Costs, Rupee Weigh
InterGlobe Aviation reported a consolidated net loss of Rs 1,879.1 crore for the July-September quarter of FY27, despite strong revenue growth.
M impact | EQUITY | Oct 29, 2026, 01:27 PM UTC
Kunlun Tech Reports Q3 Net Loss of 1.1 Billion Yuan
M impact | EQUITY | Oct 29, 2026, 01:27 PM UTC
Gulf Bourses Retreat as Bank Stocks Ease on War Worries
Gulf bourses retreated as bank stocks eased amid worries over the wars in Yemen and Iran.
M impact | EQUITY | Oct 29, 2026, 01:27 PM UTC
Cosmos Health Reports 12,050 U.S. Subscriptions, Monthly Value of $1.79M
Cosmos Health said it had 12,050 active U.S. subscriptions as of Oct. 28, up 92% in two weeks. Preliminary, unaudited monthly subscription value rose 94% to $1.79 million at standa
M impact | EQUITY | Oct 29, 2026, 01:27 PM UTC
Klabin Publishes Q3 2026 Results Presentation
Klabin published its third-quarter 2026 results presentation. The available text says net revenue rose 3%.
M impact | EQUITY | Oct 29, 2026, 01:26 PM UTC